Tower Research Capital (TRC)’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-23,199
| Closed | -$12.4K | – | 6053 |
|
|
2024
Q4 | $12.4K | Buy |
23,199
+9,434
| +69% | +$6.57K | ﹤0.01% | 3617 |
|
|
2024
Q3 | $24.2K | Sell |
13,765
-5,752
| -29% | -$8.03K | ﹤0.01% | 3133 |
|
|
2024
Q2 | $22.8K | Buy |
19,517
+19,159
| +5,352% | +$47.9K | ﹤0.01% | 3680 |
|
|
2024
Q1 | $3.24K | Sell |
358
-13,904
| -97% | -$135K | ﹤0.01% | 4899 |
|
|
2023
Q4 | $155K | Buy |
14,262
+6,721
| +89% | +$50.4K | ﹤0.01% | 2298 |
|
|
2023
Q3 | $60.7K | Buy |
7,541
+3,661
| +94% | +$30.5K | ﹤0.01% | 2382 |
|
|
2023
Q2 | $42.1K | Buy |
3,880
+1,375
| +55% | +$11.8K | ﹤0.01% | 2721 |
|
|
2023
Q1 | $17K | Sell |
2,505
-22,230
| -90% | -$139K | ﹤0.01% | 3663 |
|
|
2022
Q4 | $99K | Buy |
24,735
+23,120
| +1,432% | +$114K | ﹤0.01% | 1857 |
|
|
2022
Q3 | $11K | Sell |
1,615
-798
| -33% | -$4.91K | ﹤0.01% | 4485 |
|
|
2022
Q2 | $12K | Sell |
2,413
-2,000
| -45% | -$12.2K | ﹤0.01% | 4328 |
|
|
2022
Q1 | $41K | Buy |
4,413
+3,459
| +363% | +$34.4K | ﹤0.01% | 2891 |
|
|
2021
Q4 | $11K | Sell |
954
-472
| -33% | -$5.45K | ﹤0.01% | 4486 |
|
|
2021
Q3 | $16K | Sell |
1,426
-754
| -35% | -$10.4K | ﹤0.01% | 3946 |
|
|
2021
Q2 | $39K | Sell |
2,180
-287
| -12% | -$4.62K | ﹤0.01% | 3246 |
|
|
2021
Q1 | $38K | Sell |
2,467
-9,553
| -79% | -$138K | ﹤0.01% | 3363 |
|
|
2020
Q4 | $147K | Sell |
12,020
-15,347
| -56% | -$214K | ﹤0.01% | 2006 |
|
|
2020
Q3 | $352K | Buy |
27,367
+22,886
| +511% | +$198K | ﹤0.01% | 2043 |
|
|
2020
Q2 | $46K | Buy |
4,481
+4,266
| +1,984% | +$39.2K | ﹤0.01% | 3119 |
|
|
2020
Q1 | $2K | Buy |
+215
| New | +$1.86K | ﹤0.01% | 2665 |
|
|
2019
Q4 | – | Sell |
-448
| Closed | -$2K | – | 4559 |
|
|
2019
Q3 | $2K | Buy |
+448
| New | +$3.62K | ﹤0.01% | 3762 |
|
|
2019
Q1 | – | Sell |
-1,175
| Closed | -$14K | – | 4408 |
|
|
2018
Q4 | $14K | Buy |
1,175
+1,113
| +1,795% | +$22.5K | ﹤0.01% | 2228 |
|
|
2018
Q3 | $2K | Buy |
+62
| New | +$1.76K | ﹤0.01% | 3502 |
|
|
2018
Q2 | – | Sell |
-90
| Closed | -$1K | – | 4162 |
|
|
2018
Q1 | $1K | Sell |
90
-340
| -79% | -$8.09K | ﹤0.01% | 3121 |
|
|
2017
Q4 | $14K | Buy |
+430
| New | +$11.6K | ﹤0.01% | 2345 |
|
|
2017
Q3 | – | Sell |
-1,300
| Closed | -$14.6K | – | 4229 |
|
|
2017
Q2 | $7K | Buy |
1,300
+973
| +298% | +$5.26K | ﹤0.01% | 1844 |
|
|
2017
Q1 | $2K | Buy |
+327
| New | +$1.76K | ﹤0.01% | 2688 |
|
|
2016
Q3 | – | Sell |
-2,065
| Closed | -$10K | – | 4631 |
|
|
2016
Q2 | $10K | Buy |
2,065
+1,839
| +814% | +$33.9K | ﹤0.01% | 2846 |
|
|
2016
Q1 | $5K | Buy |
+226
| New | +$4.79K | ﹤0.01% | 2754 |
|
|
2015
Q4 | – | Sell |
-50
| Closed | -$2K | – | 5174 |
|
|
2015
Q3 | $2K | Buy |
+50
| New | +$2.82K | ﹤0.01% | 3429 |
|
|
2015
Q2 | – | Sell |
-75
| Closed | -$3K | – | 5162 |
|
|
2015
Q1 | $3K | Sell |
75
-902
| -92% | -$39.6K | ﹤0.01% | 3616 |
|
|
2014
Q4 | $41K | Sell |
977
-316
| -24% | -$9.17K | ﹤0.01% | 1150 |
|
|
2014
Q3 | $33K | Buy |
+1,293
| New | +$39.9K | ﹤0.01% | 1902 |
|
Tower Research Capital (TRC)'s MRNS Position: Q1 2025 in Review
Tower Research Capital (TRC) sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 23,199 shares — an estimated $12.4K sold.
Tower Research Capital (TRC) first reported a position in MRNS in Q3 2014 and held it in 33 quarters. The position peaked at $352K in Q3 2020. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- Tower Research Capital (TRC) reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 23,199 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $12.4K.
- Tower Research Capital (TRC) first reported a position in Marinus Pharmaceuticals, Inc in Q3 2014 and held it in 33 quarters.
- Tower Research Capital (TRC)'s Marinus Pharmaceuticals, Inc position peaked at $352K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.